• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by IN8bio Inc.

    3/17/25 4:07:32 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INAB alert in real time by email
    DEFA14A 1 d888198ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    IN8bio, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


     

     

    LOGO

     

    P.O. BOX 8016, CARY, NC 27512-9903

     

    LOGO

     

          LOGO
           

     

     

       

     

     

       

    Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

       

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On May 8, 2025 For Stockholders of record as of March 12, 2025

     

    IN8bio, Inc.

     

    Annual Meeting of Stockholders

     

    Thursday, May 8, 2025 9:00 AM, Eastern Time

     

    Annual Meeting to be held live via the internet - please visit www.proxydocs.com/INAB for more details

     

    You must register to attend the meeting online and/or participate at www.proxydocs.com/INAB

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/INAB

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

     

    If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before April 28, 2025.

     
     
       

    To order paper materials, use one of the following methods.

     

      LOGO

     

    Internet:

    www.investorelections.com/INAB

     

      LOGO

     

    Call:

    1-866-648-8133

     

      LOGO

     

    Email:

    [email protected]

     

    * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

     

     
     
       

    LOGO

       
         

     

    Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

    SEE REVERSE FOR FULL AGENDA      
    Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO    IN8bio, Inc. Annual Meeting of Stockholders

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR ALL NOMINEES FOR DIRECTOR IN PROPOSAL 1 AND FOR EACH OF PROPOSAL 2 AND PROPOSAL 3

     

     

     

    PROPOSAL

     

     

    1.    To elect the three Class I directors named in the attached proxy statement, each to serve until our 2028 Annual Meeting of Stockholders.   
       1.01 Emily Fairbairn   
       1.02 Jeremy Graff   
       1.03 Luba Greenwood   
    2.    To ratify the selection of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.   
    3.    To approve a series of alternate amendments to our Amended and Restated Certificate of Incorporation to effect, at the option of our Board of Directors, a reverse stock split of our common stock at a ratio in the range of 1-for-15 to 1-for-30, inclusive, with such ratio to be determined by our Board of Directors in its sole discretion.   
    Get the next $INAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INAB

    DatePrice TargetRatingAnalyst
    3/18/2024$7.50Buy
    Laidlaw
    8/30/2022$14.00Buy
    H.C. Wainwright
    1/24/2022$19.00 → $9.00Buy
    B. Riley Securities
    8/24/2021$12.00Buy
    Mizuho
    8/23/2021$19.00Buy
    B. Riley Securities
    More analyst ratings

    $INAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF FINANCIAL OFFICER Mccall Patrick

    4 - IN8BIO, INC. (0001740279) (Issuer)

    2/6/26 4:30:26 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by President and COO Rochlin Kate

    4 - IN8BIO, INC. (0001740279) (Issuer)

    2/6/26 4:30:23 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by EVP and CSO Lamb Lawrence

    4 - IN8BIO, INC. (0001740279) (Issuer)

    2/6/26 4:30:27 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

    NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately. Dr. Rochlin has served as IN8bio's Chief Operating Officer since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beginning in August 2020. In her expanded role, she will continue to oversee company operations as IN8bio advances its clinical and preclinical pipeline and prepares for its next

    2/9/26 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio to Present at Upcoming Investor and Scientific Conferences in February

    NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity ConferenceDate: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation: Virtual Investor Registration IO360° ConferenceDate: Thursday, February 12, 2026Time: 1:20 p.m. – 1:40 p.m. ETSession: IO Clinical Advancements Plenary Presentation title: IN8bio's Unique DeltEx D

    2/3/26 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

    Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocolMedian overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several patients who remain progression-free for multiple years (1.4 – 4.6 years) compared to only 13.2 months for SOC (+30.3%)Treatment remains well tolerated with no treatment related severe adverse events (SAEs) or dose limiting toxicities (DLTs) observed NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB

    1/12/26 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on IN8bio with a new price target

    Laidlaw initiated coverage of IN8bio with a rating of Buy and set a new price target of $7.50

    3/18/24 8:14:30 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on IN8bio with a new price target

    H.C. Wainwright initiated coverage of IN8bio with a rating of Buy and set a new price target of $14.00

    8/30/22 7:19:37 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities reiterated coverage on IN8bio with a new price target

    B. Riley Securities reiterated coverage of IN8bio with a rating of Buy and set a new price target of $9.00 from $19.00 previously

    1/24/22 9:01:28 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    SEC Filings

    View All

    SEC Form 8-K filed by IN8bio Inc.

    8-K - IN8BIO, INC. (0001740279) (Filer)

    2/9/26 8:31:05 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by IN8bio Inc.

    424B3 - IN8BIO, INC. (0001740279) (Filer)

    1/30/26 4:30:42 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by IN8bio Inc.

    SCHEDULE 13G - IN8BIO, INC. (0001740279) (Subject)

    1/29/26 3:48:25 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by IN8bio Inc.

    SC 13D/A - IN8BIO, INC. (0001740279) (Subject)

    10/11/24 6:01:16 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by IN8bio Inc.

    SC 13G - IN8BIO, INC. (0001740279) (Subject)

    10/9/24 5:19:20 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by IN8bio Inc.

    SC 13G/A - IN8BIO, INC. (0001740279) (Subject)

    9/17/24 7:30:50 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Leadership Updates

    Live Leadership Updates

    View All

    IN8bio Appoints Dr. Corinne Epperly to Board of Directors

    Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist with deep experience at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute (NCI), Goldman Sachs and most recently CARGO Therapeutics NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors. "Dr. Epperly brings an incredible range of ex

    12/7/23 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

    Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly's oncology portfolioHe is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology products NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors

    5/1/23 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board

    NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board (SAB). Dr. Bishop is Director, Hematopoietic Cellular Therapy Program, and Director of the David and Etta Jonas Center for Cellular Therapy, and Professor of Medicine at the University of Chicago. He joins the other world-renowned experts in oncology, cellular immunotherapy and immunology on IN8bio's SAB who provide expertise, contribute insights and advise the Comp

    9/8/22 7:30:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Financials

    Live finance-specific insights

    View All

    IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

    Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two yearsCompany to hos

    6/2/25 7:30:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

    100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year progression-free survival (PFS) and overall survival (OS), exceeding real-world control groups Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond one year Company to host conference call at 8:30am EST today. Use this link to participate or access the listen-only version of the webcast here NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company devel

    2/11/25 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

    100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy. The Company will host a conference call at 4:15 pm ET. Use this link to participate. A listen-only version of the webcast is available here. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clini

    6/13/24 4:01:00 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care